Differences in the time course of dopaminergic supersensitivity following chronic administration of haloperidol, molindone, or sulpiride

Psychopharmacology

Volumn 99, Issue 1, 1989, Pages 109-116

  Prosser, Elisabeth S ^a   Pruthi, Raj ^a   Csernansky, John G ^a,b  

^a VA PALO ALTO HEALTH CARE SYSTEM   (United States)

^b STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Atypical neuroleptic; Dopamine receptor; Mesolimbic; Striatum; Supersensitivity

Indexed keywords

DOPAMINE 2 RECEPTOR; HALOPERIDOL; MOLINDONE; QUINPIROLE; RADIOISOTOPE; SPIPERONE; SULPIRIDE;

ANIMAL EXPERIMENT; CORPUS STRIATUM; INTRAPERITONEAL DRUG ADMINISTRATION; LOCOMOTION; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; RECEPTOR UPREGULATION; STEREOTYPY;

ANIMAL; CORPUS STRIATUM; HALOPERIDOL; IN VITRO; INDOLES; LIMBIC SYSTEM; MALE; MOLINDONE; MOTOR ACTIVITY; RATS; RATS, INBRED STRAINS; RECEPTORS, DOPAMINE; STEREOTYPED BEHAVIOR; SULPIRIDE; SUPPORT, U.S. GOV'T, NON-P.H.S.; SUPPORT, U.S. GOV'T, P.H.S.;

EID: 0024361304     PISSN: 00333158     EISSN: 14322072     Source Type: Journal    
DOI: 10.1007/BF00634463     Document Type: Article

References (54)

1. Some atypical neuroleptics inhibit (3H)SCH-23390 binding in vivo
2. Neuroleptic inhibition of 6,7-ADTN-induced hyper-activity after injection into the nucleus accumbens: specificity and comparison with other models
3. A critical evaluation of molindone (Moban): a new indole derivative neuroleptic
4. The effect of chronic sulpiride on striatal spiperone binding
5. An original psychotropic drug: sulpiride
6. Antischizophrenic drugs: chronic treatment elevates dopamine receptor binding in brain
7. Prolonged antidopaminergic actions of single doses of butyrophenones in the rat
8. Typical and atypical neuroleptics: differential effects of chronic administration on the activity of A9 and A10 midbrain dopaminergic neurons
9. Pharmacological characterization of binding sites identified in rat brain following in vivo administration of [3H]-spiperone
10. Neuroleptic-induced supersensitivity psychosis: clinical and pharmacological characteristics
11. Pharmacological differentiation of dopamine D-1 and D-2 antagonists after single and repeated administration
12. A comparison of striatal and mesolimbic dopamine function in the rat during 6-month trifluoperazine administration
13. Mesolimbic and extrapyramidal sites for the mediation of stereotyped behavior patterns and hyperactivity by amphetamine and apomorphine in the rat
14. 3(H)-Sulpiride labels mesolimbic non-dopaminergic sites that bind antide-pressant drugs
15. In vivo modulation of brain dopamine recognition sites: a possible model for emission computed tomography studies
16. Changes in apomorphine-induced stereotypy as a result of subacute neuroleptic treatment correlates with increased D-2 receptors, but not with increases in D-1 receptors
17. Effects of chronic treatment with 1-sulpiride and haloperidol on central monoaminergic mechanisms
18. Clozapine versus chlorpromazine for the treatment of schizophrenia: preliminary results from a double-blind study
19. Extrapyramidal reactions and amine metabolites in cerebrospinal fluid during haloperidol and clozapine treatment of schizophrenic patients
20. Effects of discriminant and non-discriminant dopamine antagonists on in vivo accumulation of 3H-N-propyl-norapomorphine in mouse striatum and tuberculum olfactorium
21. Receptor-binding profiles of neuroleptics
22. Repeated administration of sulpiride for three weeks produces behavioral and biochemical evidence for cerebral dopamine receptor supersensitivity
23. Differential alteration of striatal D-1 and D-2 receptors induced by the long-term administration of haloperidol, sulpiride, or clozapine to rats
24. Increased mesolimbic dopamine binding following chronic haloperidol treatment
25. Multiple receptors for dopamine
26. Dopamine autoreceptor and postsynaptic receptor blocking potency of neuroleptics
27. The pharmacology of tardive dyskinesia
28. Neuroleptic-induced catalepsy: a D2 blockade phenomenon?
29. Regional blockade by neuroleptic drugs of in vivo 3H-spiroperidol binding in the rat brain. Relation to blockade of apomorphine induced by hyperactivity and stereotypies
30. Regional in vivo binding of the substituted benzamide [3H]eticlopride in the rat brain: evidence for selective labelling of dopamine receptors
31. Dopamine receptor binding in vivo: the feasibility of autoradiographic studies
32. In vivo blockade of dopaminergic receptors from different rat brain regions by classical and atypical neuroleptics
33. [3H]Spiperone binds selectively to rat striatal D2 dopamine receptors in vivo: a kinetics and pharmacological analysis
34. 3H-Apomorphine receptors in various rat brain regions: a study of specific and nonspecific binding and the influence of chronic neuroleptic treatment
35. Classification of neuroleptic drugs according to their ability to inhibit apomorphine-induced locomotion and gnawing: evidence for two different mechanisms of action
36. Protein measurement with the Folin phenol reagent
37. Chronic molindone treatment: relative inability to elicit dopamine receptor supersensitivity in rats
38. Dopaminergic supersensitivity after neuroleptics: Time course and specificity
39. A systematic study of the pharmacological activities of dopamine antagonists
40. The pharmacology of sulpiride: a dopamine receptor antagonist
41. Differences in the time course of haloperidol-induced up-regulation of rat striatal and mesolimbic dopamine receptors
42. The hypomotility elicited by small doses of apomorphine seems exclusively mediated by dopaminergic systems in the nucleus accumbens
43. The effect of chronic neuroleptic administration on cerebral dopamine receptor function
44. Differential alteractions in striatal dopamine receptor sensitivity induced by repeated administration of clinically equivalent doses of haloperidol, sulpiride or clozapine in rats
45. Mesolimbic dopamine function is not altered during continuous chronic treatment of rats with typical or atypical neuroleptic drugs
46. Factors contributing to the up regulation of dopaminergic receptors by chronic haloperidol
47. Brain dopamine receptors
48. Neuroleptic-induced striatal dopamine receptor supersensitivity in mice: relationship to dose and drug
49. Two dopamine receptors: biochemistry, physiology, and pharmacology
50. Effect of long-term treatment with haloperidol and sulpiride on different types of dopaminergic receptors
51. Involvement of different dopamine receptors in rat diphasic motility response to apomorphine
52. Differential, effects of classical and atypical antipsychotic drugs on A9 and A10 dopamine neurons